导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 12.39% | 566/4773 |
| 近一周 | -4.12% | 4826/5462 |
| 近一月 | -9.80% | 4865/5421 |
| 近一季 | -13.91% | 4095/5209 |
| 近半年 | 10.71% | 451/4920 |
| 近一年 | 15.46% | 675/4366 |
| 近两年 | 190.86% | 83/2954 |
| 近三年 | 137.18% | 36/2253 |
| 成立以来 | 75.98% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.41% 3617/4961 |
56.95% 446/5312 |
- - |
- - |
| 2025 | 78.74% 105/4813 |
5.21% 808/3635 |
2.42% 1578/4076 |
73.86% 14/4524 |
-4.59% 3467/4813 |
| 2024 | 20.17% 485/3463 |
-1.29% 1209/2808 |
-4.04% 1459/3014 |
16.38% 1472/3129 |
9.02% 354/3463 |
| 2023 | 8.34% 127/2656 |
39.74% 27/2280 |
-2.81% 680/2385 |
-16.84% 2261/2515 |
-4.07% 859/2655 |
| 2022 | -37.26% 1749/2207 |
-23.92% 1750/1919 |
-2.91% 1792/2016 |
-20.45% 1854/2113 |
6.78% 345/2208 |
| 2021 | 6.90% 506/1822 |
-6.73% 1033/1255 |
16.43% 202/1330 |
-9.76% 1194/1466 |
9.08% 129/1822 |
| 2020 | 11.07% 832/1250 |
0.89% 154/1028 |
13.19% 641/1067 |
-1.46% 1068/1164 |
-1.30% 1101/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华富中证人工智能产业ETF VS. 长安沪深300非周期A(740101) |